

Notice of Allowability	Application No.	Applicant(s)	
	09/807,201	SALCEDA ET AL.	
	Examiner MINH-TAM DAVIS	Art Unit 1642	

-- **The MAILING DATE of this communication appears on the cover sheet with the correspondence address--**

Claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included with (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

This communication is responsive to interview of 03/09/04.

The allowed claim(s) is/are 1.

The drawings filed on _____ are accepted by the Examiner.

Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some* c) None of the:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements set forth below. Failure to timely comply will result in ABANDONMENT of this application.
HIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.

CORRECTED DRAWINGS (as "replacement sheets") must be submitted.

(a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
1) hereto or 2) to Paper No./Mail Date _____.

(b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of
Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- Notice of References Cited (PTO-892)
- Notice of Draftsperson's Patent Drawing Review (PTO-948)
- Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date _____.
- Examiner's Comment Regarding Requirement for Deposit
of Biological Material
- Notice of Informal Patent Application (PTO-152)
- Interview Summary (PTO-413),
Paper No./Mail Date _____.
- Examiner's Amendment/Comment
- Examiner's Statement of Reasons for Allowance
- Other _____.

EXAMINER'S AMENDMENT

It is noted that Applicant's response filed March 08, 2004 placed the application in condition for allowance based on the record at that time. The Examiner's Amendment is made in lieu of reopening prosecution in order to remedy informalities which were brought to Applicant's attention for the first time in the telephone Interview of March 09, 2004. Accordingly, no further extension of time is required to make the Examiner's Amendment which places the Application fully in condition for allowance.

1. The oath or declaration is defective because:

Non-initiated and/or non-dated alterations have been made to the oath or declaration. See 37 CFR 1.52(c).

A new oath or declaration in compliance with 37 CFR 1.67(a) identifying this application by application number and filing date is required. See MPEP §§ 602.01 and 602.02

This application will not be passed to issue until a new declaration is submitted with (a) a statement acknowledging the duty to disclose material which occurred between the filing date of the prior application and the continuation-in part application, and (b) continuing data that matches the priority claimed in paragraph 1 of page 1 of the specification. See M.P.E.P. § 605.04 filed as provided by 37 C.F.R. § 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the Issue Fee.

2. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided

by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Kathleen Tyrrell on 03/09/04.

The application has been amended as follows:

In the specification:

The following continuation data has been inserted on the first line of the specification:

This application is a 371 national stage application of PCT/US99/24331, filed 10/19/1999.

In the claims:

Claim 1 was amended as follows:

A method for diagnosing the presence of prostate cancer in a patient comprising:

(a) determining the level of SEQ ID No: 7 or 8 in prostate cells, tissues or in blood, plasma, serum or urine from a patient; and
b) comparing the determined level of SEQ ID NO: 7 or 8 with the level of SEQ ID NO: 7 or 8 in prostate cells, or tissues or blood, plasma, serum or urine from a normal human control, wherein an increase in the determined level of SEQ ID NO: 7 or 8 in said patient versus normal human control is associated with the presence of prostate cancer.


Claims 2-12 have been cancelled.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MINH-TAM DAVIS whose telephone number is 571-272-0830. The examiner can normally be reached on 9:30AM-4:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, CHRISTINA CHAN can be reached on 571-272-0841. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

MINH TAM DAVIS
May 08, 2004



SUSAN UNGAR, PhD
PRIMARY EXAMINER